Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
Severe atopic dermatitis (AD) is a recurrent and debilitating disease often requiring
systemic immunosuppressive treatment. The efficacy of cyclosporine A (CsA) is well proven but
potential side effects are concerning. Several reports point at extracorporeal photopheresis
(ECP) as an efficient alternative treatment modality with few and mild side effects. However,
no direct comparison between CsA and ECP in the treatment of AD has been performed so far. In
this trial we test the hypothesis that ECP is non-inferior to standard treatment with CsA.